MedTrace Logo

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2021-01-27

No results posted yet for this study

Summary

The purpose of this study is to demonstrate a lack of effect of venlafaxine (Effexor XR) on QTc intervals relative to time matched placebo in healthy volunteers

Conditions

  • Healthy Subjects

Interventions

DRUG

Venlafaxine

Multiple doses of Venlafaxine for 14 days plus 3 days of down titration

DRUG

Moxifloxacin

400 mg single dose moxifloxacin

DRUG

Drug - placebo

Placebo administered for 16 days

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02637193 on ClinicalTrials.gov